Researcher Spotlight: Antonio Ferreira, PHD Brigham and Women’s Hospital The tumor microenvironment, comprised of both tumor cells and healthy cells, may play a role in growth and proliferation of malignant cells. Dr. Ferreira’s LRF research, funded under the Foundation’s larger…
Researcher Spotlight: Lorenzo Falchi, MD MEMORIAL SLOAN KETTERING CANCER CENTER For the last two decades, follicular lymphoma (FL) has been treated with traditional chemotherapy. While effective, this treatment is not considered curative and can cause a host of short- and…
Researcher Spotlight: Juan Alderuccio, MD MILLER SCHOOL OF MEDICINE OF THE UNIVERSITY OF MIAMI Relapsed or refractory follicular lymphoma (FL) is considered an incurable lymphoma malignancy, with most patients needing lifelong treatment. Loncastuximab tesirine is an antibody-drug conjugate that targets…
Researcher Spotlight: Patrizia Mondello, MD, PhD Mayo Clinic, Rochester Follicular lymphoma (FL) is generally slow-growing cancerwith an overall favorable prognosis. One subset, known asFL3B, has a distinctly worse clinical outcome with limited treatment options. The same treatments used to manage the other,…
Researcher Spotlight: Jason Romancik, MD Emory University – Winship Cancer Institute Follicular lymphoma (FL) is typically a slow-growingor indolent form of non- Hodgkin lymphoma (NHL)that arises from B-lymphocytes, making it a B-celllymphoma. FL is generally very responsive to radiationand chemotherapy, and most…
Researcher Spotlight: Erin Mulvey, MD Weill Cornell Medical College Diffuse large B-cell lymphoma (DLBCL) and follicularlymphoma (FL) are the two most common types of non-Hodgkin lymphoma, with one categorized as aggressive (fast-growing) and one considered indolent (slow-growing), respectively.First-line treatment for DLBCL…
Researcher Spotlight: Alexia Martinez de Paz, PhD Joan & Sanford I. Weill Medical College of Cornell University Cell-fate transitions (a biological process in which the function of a cell gets specialized, reprogrammed, or altered) during the germinal center (GC) reaction…
Researcher Spotlight: Christopher Strouse, MD The University of Iowa Follicular lymphoma (FL) is typically an indolent, or slow-growing, form of non-Hodgkin lymphoma accounts for 20 to 30 percent of all cases on non-Hodgkin lymphoma. Patients diagnosed with FL can typically…
Researcher Spotlight: Manali Kamdar, MBBS University of Colorado Patients with indolent (slow-growing) lymphomas such as follicular (FL) or marginal zone (MZL) are chronic, frequently relapsing diseases which can vary widely in clinical presentation. Therapies are varied and can often include…
Researcher Spotlight: Yuxuan Liu, PhD Columbia University Medical Center Recent research has shown that genes encoding histone acetyltransferase (HAT) enzymes, EP300 and CREBBP, often become mutated in the malignant cells of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).…